Pfizer Inc. (NYSE:PFE) Shares Acquired by Jacobs & Co. CA

Jacobs & Co. CA grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 1.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 330,023 shares of the biopharmaceutical company’s stock after buying an additional 5,190 shares during the quarter. Jacobs & Co. CA’s holdings in Pfizer were worth $9,501,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Worth Asset Management LLC purchased a new position in Pfizer during the first quarter valued at approximately $29,000. Briaud Financial Planning Inc acquired a new position in Pfizer during the 3rd quarter valued at $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new stake in Pfizer in the 3rd quarter valued at $34,000. Finally, VisionPoint Advisory Group LLC grew its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. Guggenheim assumed coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. UBS Group lowered their target price on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research note on Thursday, December 14th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research note on Thursday, January 4th. Finally, Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a research note on Thursday, December 14th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $36.88.

Pfizer Stock Up 0.7 %

Shares of PFE opened at $27.77 on Thursday. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22. The stock has a market capitalization of $157.25 billion, a price-to-earnings ratio of 77.14, a PEG ratio of 1.24 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The stock has a fifty day moving average of $27.47 and a 200-day moving average of $29.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. The firm had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period last year, the company posted $1.14 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.